Tremor in demyelinating neuropathy, a study on the prevalence, etiology and characteristics of tremor in demyelinating neuropathy

Tremor in demyelinating neuropathy, a study on the prevalence, etiology and characteristics of tremor in demyelinating neuropathy - Tremor in demyelinating neuropathy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON54557

Enrollment

260

Registered

2018-08-22

Start date

2018-09-10

Completion date

Unknown

Last updated

2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tremor in demyelinating neuropathy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with demyelinating neuropathy with and without tremor 1) CIDP For the diagnosis CIDP we will use the EFNS/PNS criteria for the diagnosis of CIDP. In addition we will include patients fulfilling the clinical criteria and at least two supportive criteria (24). 2) IgM paraproteinemic neuropathy Patients with chronic distal polyneuropathy with either axonal or demyelinating characteristics and presence of monoclonal IgM antibodies (24). 3) CMT-1A and CMT-1B Patients with uniform demyelinating polyneuropathy, genetically confirmed in patient or in a first degree relative. Patients with axonal neuropathy with and without tremor - EMG confirmed axonal polyneuropathy according to EMG examination in Amsterdam UMC or patients clinically diagnosed with a chronic axonal polyneuropathy during an outpatient clinic visit at the AMC, without an EMG examination. These patients will be included by searching electronic health records in the time frame of January 1st until December 31st 2017; - the etiology of the neuropathy is either diabetes mellitus, chronic idiopathic axonal polyneuropathy (CIAP) or medication induced (provided the causative drug cannot induce tremor) according to the last diagnosis registered and is not associated with demyelinating disorders; - neuropathy with a chronic course (symptoms for over 3 months). Additional inclusion criteria that apply to all groups above: - age >=18 years - informed consent

Exclusion criteria

Exclusion criteria: - insufficient knowledge of the Dutch language - inability to visit the hospital

Design outcomes

Primary

Measure	Time frame
The main study parameters are the prevalence of tremor in demyelinating neuropathy and the tremor characteristics.	—

Secondary

Measure	Time frame
- Association between presence of tremor and tremor severity with increase in functional disability and decrease in quality of life in patients with neuropathy, after correction for other impairment modalities such as sensory impairment and muscle weakness. - Changes in tremor severity, impairment and functioning during follow-up. - Explorative anaylsis of clinical, laboratory, fMRI and neurophysiological and fMRI characteristics of patients with tremor and patients without tremor to further elucidate the pathophysiology of tremor in demyelinating polyneuropathie. - The difference in prevalence between patients with demyelinating polyneuropathy and axonal polyneuropathy.	—

Measure

Time frame

- Association between presence of tremor and tremor severity with increase in functional disability and decrease in quality of life in patients with neuropathy, after correction for other impairment modalities such as sensory impairment and muscle weakness. - Changes in tremor severity, impairment and functioning during follow-up. - Explorative anaylsis of clinical, laboratory, fMRI and neurophysiological and fMRI characteristics of patients with tremor and patients without tremor to further elucidate the pathophysiology of tremor in demyelinating polyneuropathie. - The difference in prevalence between patients with demyelinating polyneuropathy and axonal polyneuropathy.

—

Countries

Netherlands

Outcome results